Breast Cancer

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Ecaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Elizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.

Expert discuss their expectations for research and drug development in oncology in the new year.

January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.